Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC - Nature Cancer
Source : https://www.nature.com/articles/s43018-023-00578-z
The randomized, double-blinded, multi-center, phase III GEMSTONE-302 ( NCT03789604 ) study evaluated the efficacy and safety of sugemalimab versus placebo in combination with chemotherapy as first-line treatment for metastatic non-small-cell...
Conclusions/Relevance: Sugemalimab plus chemotherapy provided superior PFS and OS compared to placebo plus chemotherapy, supporting the use of sugemalimab as a first-line treatment option for metastatic NSCLC.
Non-hyalinizing trabecular thyroid adenoma: a novel thyroid tumor with diagnostic pitfalls of hyalinizing trabecular adenoma and medullary thyroid carcinoma - Diagnostic Pathology
Source : https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-023-01361-5
Background Only one thyroid follicular cell-derived tumor with a purely trabecular growth pattern has previously been described. This report aims to describe the histological, immunohistochemical, and molecular findings of our...
Conclusions: We report our case as a novel disease entity called non-hyalinizing trabecular thyroid adenoma, which has the diagnostic pitfalls of hyalinizing trabecular tumor and medullary thyroid carcinoma.
Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37301138/
Medullary thyroid carcinoma (MTC) is a malignant tumor with challenging management. Multi-targeted kinase inhibitors (MKI) and tyrosine-kinase inhibitors (TKI) with high specificity for RET protein are approved for advanced MTC...
Conclusions/Relevance: Altogether, we showed that pralsetinib impairs MTC cell growth and induces cell death, also in hypoxic conditions. The HH-Gli pathway is a new molecular mechanism of escape to pralsetinib therapy that can be overcome through combined therapy.
Molecular testing raises thyroid nodule fine needle aspiration diagnostic value - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37310413/
Thyroid fine needle aspiration biopsy (FNAB) remains indeterminate in 16%-24% of the cases. Molecular testing could improve the diagnostic accuracy of FNAB. This study examined the gene mutation profile of...
Relevance: Thyroid fine needle aspiration biopsy (FNAB) remains indeterminate in 16%-24% of the cases. Molecular testing could improve the diagnostic accuracy of FNAB. This study examined the gene mutation profile of patients with thyroid nodules and analyzed the diagnostic ability of molecular testing for thyroid nodules using a...
NTRK Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37296928/
(1) Background: The main objectives of our study are (i) to determine the prevalence of NTRK ( neurotrophic tyrosine kinase ) fusions in a routine diagnostic setting in NSCLC (non-small...
Conclusions: In summary, we provide data on the general feasibility of NTRK screening on a large series of NSCLC samples under real-world conditions. The prevalence of NTRK fusions is 0.2% in unselected lung cancer patients. Our data indicate that a combined approach of Trk IHC pre-screening plus subsequent RNA-based...